Time-Resolved Tryptophan Fluorescence as an Indicator of Alterations in Serum Proteins in Melancholic Depression
- Autores: Syrejshchikova T.I.1, Smolina N.V.2, Brilliantova V.V.2, Syromyatnikova E.D.1, Uzbekov M.G.2, Dobretsov G.E.3
-
Afiliações:
- Lebedev Institute of Physics, Russian Academy of Sciences
- Moscow Research Institute of Psychiatry, Serbsky National Medical Research Center of Psychiatry and Addiction Psychiatry, Ministry of Health of the Russian Federation
- Federal Research and Clinical Center of Physical Chemical Medicine, Federal Medical and Biological Agency of the Russian Federation
- Edição: Volume 64, Nº 1 (2019)
- Páginas: 95-99
- Seção: Complex Systems Biophysics
- URL: https://ogarev-online.ru/0006-3509/article/view/152861
- DOI: https://doi.org/10.1134/S0006350919010184
- ID: 152861
Citar
Resumo
Abstract—The goal of this work was to search for blood serum parameters that would be associated with the state of patients with mental disorders. Such indicators are needed for an objective assessment of this state versus the prevailing subjective evaluation methodologies. The kinetics of tryptophan fluorescence decay in the serum albumin fraction was compared in patients with melancholic depression (before treatment) and in healthy volunteers. Albumin fluorescence is mainly due to the tryptophan 214 residue, which is located in the immediate vicinity of the first drug-binding center of the molecule. The decay kinetics were described as a sum of three exponential functions with lifetimes τi (in the 6.5, 2.8 and 1.0 ns region) and the amplitudes Ai. The τi values were similar in both groups of individuals. In contrast, there was a significant difference between patients and controls in the A1/A3 amplitude ratio. It is suggested that the A1/A3 value can be considered as a potential marker indicating the presence or absence of melancholic depression in patients before treatment.
Palavras-chave
Sobre autores
T. Syrejshchikova
Lebedev Institute of Physics, Russian Academy of Sciences
Email: esmoline@mail.ru
Rússia, Moscow, 119991
N. Smolina
Moscow Research Institute of Psychiatry, Serbsky National Medical Research Center of Psychiatry and Addiction Psychiatry, Ministry of Health of the Russian Federation
Autor responsável pela correspondência
Email: esmoline@mail.ru
Rússia, Moscow, 107076
V. Brilliantova
Moscow Research Institute of Psychiatry, Serbsky National Medical Research Center of Psychiatry and Addiction Psychiatry, Ministry of Health of the Russian Federation
Email: esmoline@mail.ru
Rússia, Moscow, 107076
E. Syromyatnikova
Lebedev Institute of Physics, Russian Academy of Sciences
Email: esmoline@mail.ru
Rússia, Moscow, 119991
M. Uzbekov
Moscow Research Institute of Psychiatry, Serbsky National Medical Research Center of Psychiatry and Addiction Psychiatry, Ministry of Health of the Russian Federation
Email: esmoline@mail.ru
Rússia, Moscow, 107076
G. Dobretsov
Federal Research and Clinical Center of Physical Chemical Medicine, Federal Medical and Biological Agencyof the Russian Federation
Email: esmoline@mail.ru
Rússia, Moscow, 119435
Arquivos suplementares
